Shares in PolyPeptide Group, the Swiss-based contract development and manufacturing organisation (CDMO), surged by more than 20% in morning trading on Monday, 20 July 2026, after market rumours emerged of a potential takeover bid. The stock hit a session high of CHF 34.50 on the SIX Swiss Exchange, valuing the company at approximately CHF 1.1 billion.
The rally was fuelled by speculation that a major global pharmaceutical firm is considering an acquisition of PolyPeptide to expand its capabilities in peptide-based therapeutics. Neither PolyPeptide nor any potential suitor has commented publicly, but analysts at Berenberg noted that the company's specialised manufacturing capacity for GLP-1 receptor agonists — a class of drugs used in blockbuster obesity and diabetes treatments — makes it an attractive target.
For UK investors and pension holders with exposure to European healthcare equities, the move underscores the growing appetite for contract manufacturers that support the booming metabolic drug market. The FTSE 100 edged 0.3% higher on the day, while the Stoxx Europe 600 Health Care index gained 0.8%, partly lifted by the PolyPeptide news.
Peptide-based medicines have become a key growth area in the pharmaceutical sector, driven by demand for treatments such as semaglutide and tirzepatide. PolyPeptide's order book has expanded significantly over the past year, and the company recently announced a capacity expansion at its site in Braine-l'Alleud, Belgium.
Analysts at Jefferies described the takeover speculation as 'plausible' given the scarcity of high-quality peptide CDMOs, but cautioned that no formal approach has been confirmed. 'The sector is consolidating, and PolyPeptide's niche position makes it a logical target,' they wrote in a note to clients.